These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Future of cholesteryl ester transfer protein inhibitors. Rader DJ; deGoma EM Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575 [TBL] [Abstract][Full Text] [Related]
4. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied. Masterjohn C Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377 [No Abstract] [Full Text] [Related]
5. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435 [No Abstract] [Full Text] [Related]
6. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732 [TBL] [Abstract][Full Text] [Related]
7. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Oram JF; Heinecke JW Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780 [No Abstract] [Full Text] [Related]
8. Safety of anacetrapib in patients with or at high risk for coronary heart disease. Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P; N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868 [TBL] [Abstract][Full Text] [Related]
9. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Schaefer EJ; Asztalos BF Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892 [TBL] [Abstract][Full Text] [Related]
13. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
14. HDL cholesterol and atherosclerosis. Mazzone T Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020 [No Abstract] [Full Text] [Related]
16. Anacetrapib: a potential new therapy for dyslipidemia. Robinson LB; Frishman WH Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931 [TBL] [Abstract][Full Text] [Related]
17. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon. Verma N; Figueredo VM Am J Ther; 2014; 21(3):222-32. PubMed ID: 22967983 [TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
20. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? Page MM; Hooper AJ; Burnett JR Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]